Investment and Financing Weekly Report｜Anti-tumor drugs, orthopedic robots and other financing exceeded 100 million yuan

(People's Daily Health Client Zhao Mengmeng) According to incomplete statistics of the People's Daily Health Client, this week (February 21-25), a total of 25 investment and financing events occurred in the national medical and health field, of which the financing amount exceeded 100 million yuan.

biomedicine

Gene Bio: Completed tens of millions of yuan in seed round financing, focusing on the development of universal universal cell therapy drugs

On February 22, Shenzhen Jiyin Biotechnology Co.

GeneBio is committed to the research of new tumor gene and cell therapy therapies, hoping to provide the most promising new solutions for cancer treatment in China

Yaotang Bio: Received tens of millions of angel round financing, opening a new era of LNP delivery in vivo gene editing

On February 25, Yaotang Bio, a biotechnology company focusing on combining LNP delivery and gene editing technology, announced the completion of an angel round of financing of tens of millions, exclusively invested by Xianfeng Qiyun

Founded in 2021, Yaotang (Shanghai) Biotechnology Co.

Through the continuous development and optimization of CRISPR, base editing and other new-generation gene editing tools, and innovative improvements to the next-generation mRNA production platform and lipid nanocarrier assembly process, Yaotang Bio is committed to developing treatments for hereditary diseases and heart disease.

Xueji Bio: Completed 100 million yuan pre-A round of financing to accelerate the development of new cell therapy pipelines

On February 25, Suzhou Xueji Biotechnology Co.

This round of financing will accelerate its pipeline of hematopoietic stem cells, iPSC in vitro regeneration of platelets; promote the development of platelet drug delivery platforms; and establish clinical-grade iPSC cells and their product systems for differentiation into hematopoietic lineages

Founded in June 2021, Xueji Bio is a new cell therapy company founded by returnee experts to regenerate hematopoietic lineages in vitro, with unique stem cell reprogramming, editing and differentiation technologies

medical instruments

Mingshi Junzhi: Completed Series A financing of over 50 million yuan, registered and listed speed-up products and developed new pipelines

On February 24, Mingshi Junzhi, a pioneer of miniaturization and innovative magnetic resonance, completed a series A financing of more than 50 million yuan

This round of funds will be used for the company's first phase of two products: the innovative application of the mobile fatty liver disease quantitative detector and the mid-field high-performance magnetic resonance imaging, clinical trials, NMPA/FDA registration and the development of the hospital market and brand building

Founded in 2019, Mingshi Junzhi is composed of experienced corporate managers and young scientists, and is committed to promoting the disruptive and innovative application of magnetic resonance technology in the field of medical devices

Mobi Robot: Received strategic investment from Weigao Group and joined hands to enter the field of orthopedic robots

On February 23, Shenzhen Maibu Robotics Technology Co.

Maibu Robot is a medical rehabilitation robot technology company founded by a team of returnees and senior robot industry practitioners

medical service

Dunfu Medical: Received the first round of investment of 100 million yuan led by Xinfeng Tianyu to accelerate the ecological layout of "one core and two wings" oncology medical care

On February 25, Shanghai Dunfu Medical Management Group Co.

After the completion of this round of financing, Shanghai Dunfu Hospital, a subsidiary of Dunfu Medical, will complete the second-phase expansion, and both Tianjin and Guangzhou Dunfu Hospital will be launched

Dunfu Medical established a group company in March 2020.
Its main business includes self-built and operated oncology specialist chain hospitals, multi-disease and specialized disease management of oncology, and tumor data operation and other oncology ecosystem businesses
.

Penglai Data: Completed nearly 200 million yuan in Series A financing to accelerate digital medical technology innovation

On February 23, Penglai Data announced the completion of nearly 200 million yuan in Series A financing
.
This round of financing was led by Lanchi Venture Capital and Yunqi Capital, and joined by Legend Star, Bojiang Capital, Jiaotong University Alumni Fund and Pegasus Fund
.

This round of financing will be mainly used to develop an innovative hospital operation management resource allocation optimization platform based on digital twin technology, develop an industry-oriented low-code platform, and build an industrial ecosystem through PaaS
.

Penglai Data was established in June 2010
.
The company adopts statistical methods and artificial intelligence technology to innovate methodologies and establish mathematical models in performance evaluation and incentive system construction, hospital operation analysis, cost control, resource allocation, hospital strategy analysis and quantitative evaluation of discipline development.
Practical application in a large hospital
.